CD4 CAR T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCD4 CAR T cell therapy (iCell Gene Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT-cell surface antigen CD4 modulatorsT lymphocyte replacements

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesiCell Gene Therapeutics LLC iCar Bio Therapeutics Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, T-Cell

Other Information

ATC CodeN/A